PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions.
Antigens (neoplasm)
Fluorodeoxyglucose F18
Immunotherapy
Positron emission tomography computed tomography
Receptors (chimeric antigen)
Journal
European radiology experimental
ISSN: 2509-9280
Titre abrégé: Eur Radiol Exp
Pays: England
ID NLM: 101721752
Informations de publication
Date de publication:
17 11 2020
17 11 2020
Historique:
received:
03
07
2020
accepted:
13
10
2020
entrez:
17
11
2020
pubmed:
18
11
2020
medline:
6
7
2021
Statut:
epublish
Résumé
Recent immunotherapeutic approaches have evolved as powerful treatment options with high anti-tumour responses involving the patient's own immune system. Passive immunotherapy applies agents that enhance existing anti-tumour responses, such as antibodies against immune checkpoints. Active immunotherapy uses agents that direct the immune system to attack tumour cells by targeting tumour antigens. Active cellular-based therapies are on the rise, most notably chimeric antigen receptor T cell therapy, which redirects patient-derived T cells against tumour antigens. Approved treatments are available for a variety of solid malignancies including melanoma, lung cancer and haematologic diseases. These novel immune-related therapeutic approaches can be accompanied by new patterns of response and progression and immune-related side-effects that challenge established imaging-based response assessment criteria, such as Response Evaluation Criteria in Solid tumours (RECIST) 1.1. Hence, new criteria have been developed. Beyond morphological information of computed tomography (CT) and magnetic resonance imaging, positron emission tomography (PET) emerges as a comprehensive imaging modality by assessing (patho-)physiological processes such as glucose metabolism, which enables more comprehensive response assessment in oncological patients. We review the current concepts of response assessment to immunotherapy with particular emphasis on hybrid imaging with
Identifiants
pubmed: 33200246
doi: 10.1186/s41747-020-00190-1
pii: 10.1186/s41747-020-00190-1
pmc: PMC7669926
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Références
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):238-250
pubmed: 30291373
ESMO Open. 2018 Jan 13;3(1):e000278
pubmed: 29387476
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):386-96
pubmed: 25359635
Int J Mol Sci. 2019 May 30;20(11):
pubmed: 31151303
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29
pubmed: 29796651
J Clin Oncol. 2015 Nov 1;33(31):3541-3
pubmed: 26261262
J Clin Oncol. 2018 May 10;36(14):1428-1439
pubmed: 29584546
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762
pubmed: 30361681
Cancer Res. 2017 May 1;77(9):2318-2327
pubmed: 28461564
JAMA Oncol. 2016 Oct 1;2(10):1346-1353
pubmed: 27367787
Clin Cancer Res. 2016 Sep 15;22(18):4550-5
pubmed: 27435397
Immunol Res. 2014 Aug;59(1-3):203-10
pubmed: 24906530
Cancer Sci. 2017 May;108(5):1007-1012
pubmed: 28267244
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1158-1167
pubmed: 31760467
Cancers (Basel). 2020 Jan 03;12(1):
pubmed: 31947775
Leuk Lymphoma. 2009 Aug;50(8):1257-60
pubmed: 19544140
Invest New Drugs. 2018 Aug;36(4):638-646
pubmed: 29159766
Leuk Lymphoma. 2019 Feb;60(2):367-375
pubmed: 30032683
Oncotarget. 2018 Jul 13;9(54):30268-30278
pubmed: 30100988
Blood. 1970 Jun;35(6):741-50
pubmed: 4913404
Front Immunol. 2015 Jul 27;6:368
pubmed: 26284063
Pigment Cell Melanoma Res. 2016 Sep;29(5):572-7
pubmed: 27333363
J Clin Oncol. 1999 Apr;17(4):1244
pubmed: 10561185
Nat Med. 2018 May;24(5):539-540
pubmed: 29736024
Clin Immunol. 2014 Dec;155(2):160-75
pubmed: 25444722
J Nucl Med. 2020 May;61(5):649-654
pubmed: 31628220
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Leukemia. 2003 May;17(5):900-9
pubmed: 12750704
J Hematol Oncol. 2020 Jan 3;13(1):1
pubmed: 31900191
Semin Nucl Med. 2009 Sep;39(5):308-40
pubmed: 19646557
Blood. 2016 Nov 24;128(21):2489-2496
pubmed: 27574190
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2310-2325
pubmed: 28815334
Radiology. 2019 Jan;290(1):9-22
pubmed: 30457485
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
N Engl J Med. 2020 Feb 6;382(6):545-553
pubmed: 32023374
Ann Hematol. 2017 Apr;96(4):647-651
pubmed: 28138786
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
J Thorac Oncol. 2018 Nov;13(11):1733-1742
pubmed: 29775807
Annu Rev Immunol. 2001;19:565-94
pubmed: 11244047
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
Mol Imaging Biol. 2017 Dec;19(6):903-914
pubmed: 28247187
Oncologist. 2017 Apr;22(4):470-479
pubmed: 28275115
Biologics. 2020 Feb 14;14:23-34
pubmed: 32103893
Cell. 2020 Apr 2;181(1):46-62
pubmed: 32243795
Bioconjug Chem. 2015 Oct 21;26(10):2062-9
pubmed: 26307602
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
J Clin Invest. 2020 Apr 1;130(4):1586-1594
pubmed: 32235098
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Cancer Res. 2018 Oct 1;78(19):5706-5717
pubmed: 30115693
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296
pubmed: 29478079
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383
pubmed: 29124281
Immunol Lett. 2019 Jul;211:13-22
pubmed: 31091431
Ann Oncol. 2017 Jul 1;28(7):1605-1611
pubmed: 28419181
Radiology. 2020 Jun;295(3):651-661
pubmed: 32286191
J Clin Invest. 2019 Mar 21;129(6):2210-2221
pubmed: 30896447
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
Front Oncol. 2019 Mar 26;9:176
pubmed: 30984613
Biol Blood Marrow Transplant. 2019 Jun;25(6):1092-1098
pubmed: 30769193
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32753543
Front Immunol. 2020 Mar 05;11:176
pubmed: 32194541
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
J Nucl Med. 2018 Jan;59(1):15-24
pubmed: 28596157
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
J Clin Invest. 2013 Dec;123(12):5098-103
pubmed: 24177426
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Clin Cancer Res. 2020 Aug 15;26(16):4414-4425
pubmed: 32253232
Cancer Res Treat. 2018 Oct;50(4):1462-1466
pubmed: 29397660
J Immunother Cancer. 2016 Sep 20;4:58
pubmed: 27660712
Cancer Res. 2019 Jan 15;79(2):387-396
pubmed: 30482775
J Nucl Med. 2017 Sep;58(9):1421-1428
pubmed: 28360208
Acad Radiol. 2017 Jan;24(1):111-115
pubmed: 27818005
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):56-66
pubmed: 28828507
Ann Oncol. 2017 Oct 1;28(10):2377-2385
pubmed: 28945858
Ann Oncol. 2017 Jul 1;28(7):1436-1447
pubmed: 28379322
J Clin Invest. 2014 Feb;124(2):812-23
pubmed: 24430180
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Eur J Cancer. 2018 Mar;91:136-144
pubmed: 29360605
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
Cytotherapy. 2018 Dec;20(12):1415-1418
pubmed: 30385043
J Clin Oncol. 2016 Nov 1;34(31):3733-3739
pubmed: 27354476
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
PET Clin. 2020 Jan;15(1):35-43
pubmed: 31735300
Am J Hematol. 2018 Jun 8;:
pubmed: 29884994
Clin Nucl Med. 2019 Apr;44(4):e272-e279
pubmed: 30688730
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219